#BEGIN_DRUGCARD DB02703

# AHFS_Codes:
Not Available

# ATC_Codes:
D06AX01
D09AA02
J01XC01
S01AA13

# Absorption:
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.

# Biotransformation:
Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.

# Brand_Mixtures:
Fucibet (Fusidic acid + betamethasone)
Fucicort (Fusidic acid + hydrocortisone)

# Brand_Names:
Fucidin
Fucidin Cream 2%
Fucidin acid
Fucidine
Fucithalmic
Fusidine
Ramycin

# CAS_Registry_Number:
6990-06-3

# ChEBI_ID:
29013

# Chemical_Formula:
C31H48O6

# Chemical_IUPAC_Name:
2-[(1S,2S,5R,6S,7S,10S,11S,13S,14Z,15R,17R)-13-(acetyloxy)-5,17-dihydroxy-2,6,10,11-tetramethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-ylidene]-6-methylhept-5-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
586668

# Description:
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Bacterial Agents
Antibacterial Agents
Protein Synthesis Inhibitors

# Drug_Interactions:
Amprenavir	The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
Atorvastatin	Increased risk of myopathy/rhabdomyolysis
Fosamprenavir	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
Indinavir	Indinavir may increase the effect and toxicity of fusidic acid.
Nelfinavir	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
Penicillin V	Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
Ritonavir	The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
Saquinavir	The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
Simvastatin	Increased risk of myopathy/rhabdomyolysis
Ticarcillin	Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
Tipranavir	Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Take with food to reduce irritation.

# GenBank_ID:
Not Available

# Generic_Name:
Fusidic Acid

# HET_ID:
FUA

# Half_Life:
Approximately 5 to 6 hours in adults.

# InChI_Identifier:
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1

# InChI_Key:
InChIKey=IECPWNUMDGFDKC-MZJAQBGESA-N

# Indication:
For the treatment of bacterial infections.

# KEGG_Compound_ID:
C06694

# KEGG_Drug_ID:
D04281

# LIMS_Drug_ID:
2703

# Mechanism_Of_Action:
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.

# Melting_Point:
192.5 Â°C

# Molecular_Weight_Avg:
516.7092

# Molecular_Weight_Mono:
516.345089268

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1QCA

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749648

# Pharmacology:
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.

# Predicted_LogP_Hydrophobicity:
4.97

# Predicted_LogS:
-5

# Predicted_Water_Solubility:
5.21e-03 g/l

# Primary_Accession_No:
DB02703

# Protein_Binding:
97 to 99%

# PubChem_Compound_ID:
3000226

# PubChem_Substance_ID:
46505364

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01507

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Diethanolamine fusidate
Fucidate
Fucidate Sodium
Fucidic acid
Fusidate
Fusidate Sodium

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:24 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Fusidic_acid

# pKa_Isoelectric_Point:
5.35

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
19289529	Lannergard J, Norstrom T, Hughes D: Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. Epub 2009 Mar 16.
19833919	Gao YG, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V: The structure of the ribosome with elongation factor G trapped in the posttranslocational state. Science. 2009 Oct 30;326(5953):694-9.
20718859	Chen Y, Koripella RK, Sanyal S, Selmer M: Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acid. FEBS J. 2010 Sep;277(18):3789-803.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fusA

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
11054294	Laurberg M, Kristensen O, Martemyanov K, Gudkov AT, Nagaev I, Hughes D, Liljas A: Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol. 2000 Nov 3;303(4):593-603.
8736554	al-Karadaghi S, Aevarsson A, Garber M, Zheltonosova J, Liljas A: The structure of elongation factor G in complex with GDP: conformational flexibility and nucleotide exchange. Structure. 1996 May 15;4(5):555-65.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3270

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
76880

# Drug_Target_1_Name:
Elongation factor G

# Drug_Target_1_Number_of_Residues:
691

# Drug_Target_1_PDB_ID:
1KTV

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00009	GTP_EFTU
PF00679	EFG_C
PF03144	GTP_EFTU_D2
PF03764	EFG_IV

# Drug_Target_1_Protein_Sequence:
>Elongation factor G
MAVKVEYDLKRLRNIGIAAHIDAGKTTTTERILYYTGRIHKIGEVHEGAATMDFMEQERE
RGITITAAVTTCFWKDHRINIIDTPGHVDFTIEVERSMRVLDGAIVVFDSSQGVEPQSET
VWRQAEKYKVPRIAFANKMDKTGADLWLVIRTMQERLGARPVVMQLPIGREDTFSGIIDV
LRMKAYTYGNDLGTDIREIPIPEEYLDQAREYHEKLVEVAADFDENIMLKYLEGEEPTEE
ELVAAIRKGTIDLKITPVFLGSALKNKGVQLLLDAVVDYLPSPLDIPPIKGTTPEGEVVE
IHPDPNGPLAALAFKIMADPYVGRLTFIRVYSGTLTSGSYVYNTTKGRKERVARLLRMHA
NHREEVEELKAGDLGAVVGLKETITGDTLVGEDAPRVILESIEVPEPVIDVAIEPKTKAD
QEKLSQALARLAEEDPTFRVSTHPETGQTIISGMGELHLEIIVDRLKREFKVDANVGKPQ
VAYRETITKPVDVEGKFIRQTGGRGQYGHVKIKVEPLPRGSGFEFVNAIVGGVIPKEYIP
AVQKGIEEAMQSGPLIGFPVVDIKVTLYDGSYHEVDSSEMAFKIAGSMAIKEAVQKGDPV
ILEPIMRVEVTTPEEYMGDVIGDLNARRGQILGMEPRGNAQVIRAFVPLAEMFGYATDLR
SKTQGRGSFVMFFDHYQEVPKQVQEKLIKGQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This protein promotes the GTP-dependent translocation of the nascent protein chain from the A-site to the P-site of the ribosome

# Drug_Target_1_SwissProt_ID:
P13551

# Drug_Target_1_SwissProt_Name:
EFG_THETH

# Drug_Target_1_Synonyms:
EF-G

# Drug_Target_1_Theoretical_pI:
5.09

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6354181	Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38.
7500366	Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005.
7756272	Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AL513383

# Drug_Target_2_GenBank_ID_Protein:
16505914

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
cat

# Drug_Target_2_Gene_Sequence:
>660 bp
ATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAA
CATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGAT
ATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATT
CACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGT
GAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAA
ACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATAT
TCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAG
AATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTG
GCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGC
GACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCAT
GTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAA

# Drug_Target_2_General_Function:
Involved in chloramphenicol O-acetyltransferase activity

# Drug_Target_2_General_References:
11677608	Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, Churcher C, Mungall KL, Bentley SD, Holden MT, Sebaihia M, Baker S, Basham D, Brooks K, Chillingworth T, Connerton P, Cronin A, Davis P, Davies RM, Dowd L, White N, Farrar J, Feltwell T, Hamlin N, Haque A, Hien TT, Holroyd S, Jagels K, Krogh A, Larsen TS, Leather S, Moule S, O'Gaora P, Parry C, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG: Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature. 2001 Oct 25;413(6858):848-52.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3278

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
25663

# Drug_Target_2_Name:
Chloramphenicol acetyltransferase

# Drug_Target_2_Number_of_Residues:
219

# Drug_Target_2_PDB_ID:
1Q23

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00302	CAT

# Drug_Target_2_Protein_Sequence:
>Chloramphenicol acetyltransferase
MEKKITGYTTVDISQWHRKEHFEAFQSVAQCTYNQTVQLDITAFLKTVKKNKHKFYPAFI
HILARLMNAHPEFRMAMKDGELVIWDSVHPCYTVFHEQTETFSSLWSEYHDDFRQFLHIY
SQDVACYGENLAYFPKGFIENMFFVSANPWVSFTSFDLNVANMDNFFAPVFTMGKYYTQG
DKVLMPLAIQVHHAVCDGFHVGRMLNELQQYCDEWQGGA

# Drug_Target_2_Reaction:
acetyl-CoA + chloramphenicol = CoA + chloramphenicol 3-acetate

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This enzyme is an effector of chloramphenicol resistance in bacteria

# Drug_Target_2_SwissProt_ID:
P62580

# Drug_Target_2_SwissProt_Name:
CAT_SALTI

# Drug_Target_2_Synonyms:
CAT
EC 2.3.1.28

# Drug_Target_2_Theoretical_pI:
6.36

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6354181	Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38.
7500366	Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005.
7756272	Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X07848

# Drug_Target_3_GenBank_ID_Protein:
47025

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
cat3

# Drug_Target_3_Gene_Sequence:
>642 bp
ATGAACTATACAAAATTTGATGTAAAAAATTGGGTTCGCCGTGAGCATTTTGAGTTTTAT
CGGCATCGTTTACCATGTGGTTTTAGCTTAACAAGCAAAATTGATATCACGACGTTAAAA
AAGTCATTGGATGATTCAGCGTATAAGTTTTATCCGGTAATGATCTATCTGATTGCTCAG
GCCGTGAATCAATTTGATGAGTTGAGAATGGCGATAAAAGATGATGAATTGATCGTATGG
GATTCAGTCGACCCACAATTCACCGTATTCCATCAAGAAACAGAGACATTTTCAGCACTG
AGTTGCCCATACTCATCCGATATTGATCAATTTATGGTGAATTATTTATCGGTAATGGAA
CGTTATAAAAGTGATACCAAGTTATTTCCTCAAGGGGTAACACCAGAAAATCATTTAAAT
ATTTCAGCATTACCTTGGGTTAATTTTGATAGCTTTAATTTAAATGTTGCTAATTTTACC
GATTATTTTGCACCCATTATAACAATGGCAAAATATCAGCAAGAAGGGGATAGACTGTTA
TTGCCGCTCTCAGTACAGGTTCATCATGCAGTTTGTGATGGCTTCCATGTTGCACGCTTT
ATTAATCGGCTACAAGAGTTGTGTAACAGTAAATTAAAATAA

# Drug_Target_3_General_Function:
Involved in chloramphenicol O-acetyltransferase activity

# Drug_Target_3_General_References:
2187098	Leslie AG: Refined crystal structure of type III chloramphenicol acetyltransferase at 1.75 A resolution. J Mol Biol. 1990 May 5;213(1):167-86.
3048245	Murray IA, Hawkins AR, Keyte JW, Shaw WV: Nucleotide sequence analysis and overexpression of the gene encoding a type III chloramphenicol acetyltransferase. Biochem J. 1988 May 15;252(1):173-9.
3288984	Leslie AG, Moody PC, Shaw WV: Structure of chloramphenicol acetyltransferase at 1.75-A resolution. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4133-7.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2808

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
24994

# Drug_Target_3_Name:
Chloramphenicol acetyltransferase 3

# Drug_Target_3_Number_of_Residues:
213

# Drug_Target_3_PDB_ID:
3CLA

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00302	CAT

# Drug_Target_3_Protein_Sequence:
>Chloramphenicol acetyltransferase 3
MNYTKFDVKNWVRREHFEFYRHRLPCGFSLTSKIDITTLKKSLDDSAYKFYPVMIYLIAQ
AVNQFDELRMAIKDDELIVWDSVDPQFTVFHQETETFSALSCPYSSDIDQFMVNYLSVME
RYKSDTKLFPQGVTPENHLNISALPWVNFDSFNLNVANFTDYFAPIITMAKYQQEGDRLL
LPLSVQVHHAVCDGFHVARFINRLQELCNSKLK

# Drug_Target_3_Reaction:
acetyl-CoA + chloramphenicol = CoA + chloramphenicol 3-acetate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
This enzyme is an effector of chloramphenicol resistance in bacteria

# Drug_Target_3_SwissProt_ID:
P00484

# Drug_Target_3_SwissProt_Name:
CAT3_ECOLX

# Drug_Target_3_Synonyms:
Chloramphenicol acetyltransferase III
EC 2.3.1.28
catIII

# Drug_Target_3_Theoretical_pI:
6.15

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB02703
